Group 1 - The stock price of Saint Noble Pharmaceuticals-B (02257.HK) has increased by over 18%, with a cumulative increase of more than 90% in the month [1] - As of the latest update, the stock is trading at 17.79 HKD, with a trading volume of 45.3042 million HKD [1]

Group 1 - Saint Noble Pharmaceuticals-B (02257.HK) has seen its stock price increase by over 18%, with a cumulative increase of more than 90% in the month [1] - As of the latest update, the stock is trading at 17.79 HKD, with a trading volume of 45.3042 million HKD [1]

Core Viewpoint - Saint Noble Pharmaceuticals (2257.HK) plans to issue 17.35 million new shares to four investors, including Shanghai-listed Huaxi Biotechnology, at a price of HKD 12 per share, representing a discount of 19.84% from the last closing price of HKD 14.97. The fundraising aims to raise approximately HKD 208 million, with a net amount of about HKD 206 million, to be used for general working capital [1] Group 1 - The share issuance represents approximately 14.16% of the enlarged share capital [1] - The company believes that the subscription will benefit its long-term development and provide an opportunity to raise additional funds [1] - The funds raised will strengthen the company's financial position and expand its shareholder and capital base, promoting future business growth and development [1] Group 2 - The transaction is expected to enhance the liquidity of the company's shares [1]

Group 1 - The core point of the article is that Sanofi Pharmaceuticals-B (02257) experienced a stock price increase of over 10%, reaching HKD 16.51 with a trading volume of HKD 5.1769 million [1] - Sanofi Pharmaceuticals-B announced plans to issue 17.3524 million subscription shares, representing approximately 14.16% of the company's enlarged issued share capital, to specific subscribers [1] - The subscription price is set at HKD 12.00 per share, which is a discount of about 19.84% compared to the closing price of HKD 14.97 on September 5 [1] Group 2 - The total amount raised from the subscription is expected to be approximately HKD 208.2 million, with a net amount of about HKD 206 million [1] - The company intends to use the proceeds from the subscription for general working capital [1]

Group 1 - The company, Sanofi Pharma-B, plans to issue 17.3524 million subscription shares to Huaxi Biotechnology (Hong Kong) Limited, Mr. Xie Shuohao, Bamboo Bloom Limited, and Capstone Resources Holding Limited [1] - This issuance represents approximately 14.16% of the company's enlarged issued share capital [1] - The subscription price is set at HKD 12.00 per share, which is a discount of about 19.84% compared to the closing price of HKD 14.97 on September 5 [1] Group 2 - The total funds expected to be raised from this issuance are approximately HKD 208.2 million, with a net amount of about HKD 206 million [1] - The funds will be utilized for the company's general working capital [1]

Group 1 - The company, Sanofi Pharmaceutical-B (02257.HK), announced a subscription agreement to issue 17.3524 million shares at a subscription price of HKD 12.00 per share [1] - The total shares to be issued represent approximately 16.50% of the company's existing issued share capital and about 14.16% of the enlarged issued share capital after the issuance [1] - The subscription price of HKD 12.00 per share reflects a discount of approximately 19.84% compared to the closing price of HKD 14.97 on September 5, the last trading day before the agreement [1] Group 2 - The total proceeds from the subscription are expected to be approximately HKD 208.2 million, with net proceeds around HKD 206 million [1] - The company plans to use the proceeds from the subscription for general working capital [1] - The subscribers include Huaxi Biotechnology (Hong Kong) Co., Ltd., Mr. Xie Shuohao, Bamboo Bloom Limited, and Capstone Resources Holding Limited [1]

Group 1 - The core announcement is that Sanofi Pharmaceutical-B plans to issue 17.3524 million subscription shares, representing approximately 14.16% of the company's enlarged issued share capital as of September 7, 2025 [2] - The subscription price is set at HKD 12 per share, which reflects a discount of about 19.84% compared to the closing price of HKD 14.97 on September 5 [2]

Group 1 - The company, Saint Noble Pharmaceuticals-B (02257), plans to issue 17.3524 million subscription shares, representing approximately 14.16% of the enlarged issued share capital after the issuance [1] - The subscription price is set at HKD 12.00 per share, which is a discount of about 19.84% compared to the closing price of HKD 14.97 on September 5 [1] - The total amount raised from the subscription is expected to be approximately HKD 208.2 million, with a net amount of about HKD 206 million intended for general working capital [1]

Group 1 - The company plans to issue 17.3524 million subscription shares, representing approximately 14.16% of the enlarged issued share capital after the issuance [1] - The subscription price is set at HKD 12.00 per share, which is a discount of about 19.84% compared to the closing price of HKD 14.97 on September 5 [1] - The total amount raised from the subscription is expected to be approximately HKD 208.2 million, with a net amount of about HKD 206 million to be used for general working capital [1]

香 港 交易 及 結 算 所 有限 公 司 及 香港 聯 合 交 易 所有 限 公 司 對 本公 告 的 內 容概 不 負 責， 對 其 準 確 性或 完 整 性 亦不 發 表 任 何 聲明 ， 並 明 確 表示 ， 概 不 對因 本 公 告全 部 或 任 何 部份 內 容 而 產生 或 因 倚 賴 該等 內 容 而 引 致的 任 何 損 失承 擔任何責任。 本 公 告 僅 供 參 考 ， 並不 構 成 收 購、 購 買 或 認 購本 公 司 任 何 證券 的 邀 請 或要 約。 Sirnaomics Ltd. 聖 諾 醫 藥 * 於開曼群島註冊成立的有限公司） （股份代號：2257） 根據一般授權認購新股份 董事會欣然宣佈，於2025年9月7日，本公司（ 作為發行人 ）與該等 認購人 訂 立 該 等 認 購 協 議 ， 內 容 有 關 按 認 購 價 每 股 認 購 股 份 12.00 港 元 認 購 17,352,421股認購股份。 發 行 認 購 股 份 將 無 須 獲 得 股 東 批 准 而 認 購 股 份 將 根 據 一 般 授 權 予 以 發 行。 鑒 於 認 購 事 項 須 待 該 等 認 購 ...